Key Findings
-
Hepatocellular Carcinoma market size projection: As per DelveInsight’s analysis, the total market size of Hepatocellular Carcinoma in the 7MM is expected to reach USD XX million by 2034.
-
Hepatocellular Carcinoma market drivers: Key market drivers of Hepatocellular Carcinoma include the rising incidence of liver cancer (which has tripled in the last four decades), increased awareness initiatives, improved diagnosis rates, introduction of emerging therapies with enhanced efficacy, and significant research and development activities.
-
Hepatocellular Carcinoma epidemiology: The report provides the total Hepatocellular Carcinoma potential pool with segmentation including Total Incident Cases, Stage-wise Patients, and Total Treated Cases across the 7MM. According to SEER data, the US incidence rate is 9.0 per 100,000, translating to approximately 42,230 new diagnosed cases in 2021, with a 5-year survival rate of 20.3%.
-
Key Hepatocellular Carcinoma companies: Leading Hepatocellular Carcinoma companies include Eli Lilly, Merck, Genentech, GlaxoSmithKline, Bristol-Myers Squibb, H3 Biomedicine, Genoscience Pharma, Kymab, Sanofi, Exelixis, Zymeworks, Sirtex Medical, and Mursla Bio.
-
Hepatocellular Carcinoma pipeline assets: Key Hepatocellular Carcinoma therapies in the pipeline include H3B-6527, GNS561, SAR445256 (Alomfilimab), ZW251, amezalpat (TPST-1120), RZ-001, LioCyx-M004, and SIR-Spheres Y-90 resin microspheres.
-
Recent developments: 2025 has marked a transformative year for HCC therapeutics with multiple breakthrough approvals including FDA approval of nivolumab plus ipilimumab for first-line treatment (April 2025), SIR-Spheres Y-90 resin microspheres approval for unresectable HCC (July 2025), FDA clearance of ZW251 IND application (July 2025), and breakthrough device designation for EvoLiver test (April 2025).
Discover more recent advancements in the Hepatocellular Carcinoma landscape @ Hepatocellular Carcinoma Recent Developments.
Hepatocellular Carcinoma Market Intelligence
The Hepatocellular Carcinoma market represents one of the most rapidly evolving oncology segments, driven by substantial unmet medical needs and innovative therapeutic approaches. The market encompasses the 7MM including the United States, EU4 countries (Germany, France, Italy, Spain), United Kingdom, and Japan, with a study period spanning 2020 to 2034 and forecast period from 2025 to 2034.
DelveInsight’s comprehensive Hepatocellular Carcinoma Market Insight, Epidemiology And Market Forecast report projects the HCC market to reach USD XX million by 2034, representing significant growth from current levels. The market dynamics are anticipated to witness major transformation during the study period 2020-2034, driven by robust pipeline developments and increased research activities. The therapy market includes six FDA-approved immunotherapy options, with several others currently undergoing clinical trials including oncolytic viruses and adoptive cell therapy.
The Hepatocellular Carcinoma market growth is propelled by multiple factors including the rising global incidence of liver cancer, which has tripled over the past four decades, yet maintains poor prognosis for patients. Enhanced awareness initiatives, improved diagnostic capabilities, and substantial increases in research and development investments across pharmaceutical companies contribute significantly to market expansion. The expected introduction of emerging therapies with improved efficacy profiles, combined with label expansions of approved therapies, further accelerates market growth potential.
DelveInsight’s geographical analysis shows that the United States represents the largest market segment within the 7MM, followed by EU5 countries and Japan, with each region projected to reach USD XX million respectively. Regional variations in treatment patterns, regulatory approvals, and healthcare infrastructure contribute to distinct market dynamics across these territories. The geographic distribution reflects varying epidemiological patterns, with certain regions experiencing higher incidence rates correlating with underlying risk factors including hepatitis prevalence and lifestyle factors.
Furthermore, the comprehensive epidemiological analysis reveals Total Incident Cases of Hepatocellular Carcinoma, Stage-wise Patient distribution, and Total Treated Cases across the 7MM from 2020 to 2034. Stage-wise distribution shows Localized (45%), Regional (26%), Distant (18%), and Unknown (11%) categories, providing crucial insights for treatment planning and market segmentation. The mortality rate stands at 6.6 per 100,000 per year with survival rates remaining challenging, highlighting significant opportunities for therapeutic intervention.
For a deeper analysis of the evolving Hepatocellular Carcinoma market, download our free sample report.
Hepatocellular Carcinoma Competitive Landscape
The competitive landscape encompasses established pharmaceutical giants and innovative biotechnology companies pursuing diverse therapeutic approaches. Key players include Bristol-Myers Squibb with OPDIVO (nivolumab) and YERVOY (ipilimumab) combination therapy, which received FDA approval for first-line treatment in April 2025, demonstrating statistically significant overall survival benefit with 38% of patients remaining alive at 3 years compared to 24% with comparator therapies. Genentech’s TECENTRIQ (atezolizumab) combined with bevacizumab represents another cornerstone first-line treatment approved for advanced HCC patients.
Merck’s KEYTRUDA (pembrolizumab) targets specific patient subsets with advanced HCC, including those with high microsatellite instability, DNA mismatch repair deficiency, or high tumor mutational burden. GlaxoSmithKline’s JEMPERLI (dostarlimab) addresses patients with DNA mismatch repair deficiency, while the targeted therapy landscape includes AVASTIN (bevacizumab) approved in combination with atezolizumab.
Clinical pipeline activity demonstrates unprecedented vigor with companies advancing novel mechanisms including H3 Biomedicine’s H3B-6527 (FGFR4 inhibitor), Genoscience Pharma’s GNS561 (autophagy inhibitor), and Sanofi’s SAR445256 (ICOS agonist). Development phases span from preclinical through Phase III, with multiple ongoing studies evaluating combination approaches and novel targets across diverse patient populations.
Furthermore, Genentech continues advancing their TECENTRIQ (atezolizumab) plus bevacizumab combination, approved as first-line treatment for advanced HCC subsets, leveraging PD-L1 pathway inhibition combined with VEGF-A targeting to deliver comprehensive therapeutic approach. Merck’s KEYTRUDA (pembrolizumab) addresses precision medicine approaches, targeting patients with specific biomarker profiles including high microsatellite instability and DNA mismatch repair deficiency.
Innovative biotechnology companies are reshaping the competitive landscape through breakthrough technologies. Zymeworks achieved significant milestone with FDA clearance of ZW251 IND application in July 2025, advancing their novel glypican-3 targeted antibody-drug conjugate incorporating proprietary topoisomerase 1 inhibitor payload for HCC treatment, with Phase 1 trials expected to commence in 2025. Sirtex Medical transformed interventional oncology with FDA approval of SIR-Spheres Y-90 resin microspheres for unresectable HCC in July 2025, achieving remarkable 98.5% overall response rate with 100% local tumor control rate in the DOORwaY90 study, making it the only radioembolization therapy approved for both HCC and metastatic colorectal cancer in the United States.
Mursla Bio received breakthrough device designation for EvoLiver in April 2025, pioneering dynamic biopsy technology utilizing organ-specific extracellular vesicles for HCC surveillance in high-risk cirrhotic patients, demonstrating 86% early-stage sensitivity at 88% specificity. Development milestones include regulatory designations with Tempest Therapeutics receiving orphan drug designation and fast track designation for amezalpat (TPST-1120), while Rznomics achieved fast track designation for RZ-001 RNA substitution enzyme-based gene therapy. Commercial arrangements encompass strategic collaborations across industry-academia partnerships, with licensing deals supporting diverse pipeline advancement and regulatory milestone achievements driving market expansion.
Delve deeper into the major and specialised companies in the Hepatocellular Carcinoma market @ Hepatocellular Carcinoma Competitive Landscape.
Hepatocellular Carcinoma Market Drivers and Barriers
The Hepatocellular Carcinoma market faces substantial unmet medical needs driving innovation and investment across therapeutic development. Primary unmet needs include addressing the poor prognosis associated with advanced HCC, where patients typically have significant underlying liver disease associated with poor tolerability to systemic chemotherapy. The high recurrence rates following successful surgeries, reaching 50% or higher among patients, represent critical challenges requiring innovative therapeutic approaches. Current treatment limitations include the 5-year survival rate of only 20.3% and disease progression occurring within 56 to 155 days for patients without significant tumor response.
Additional market drivers encompass the rising global incidence of liver cancer, which has tripled over the past four decades yet maintains challenging patient outcomes. The fastest-growing cause of cancer-related deaths, HCC surveillance adherence remains low with standard ultrasound-based methods demonstrating limited sensitivity, particularly for detecting small tumors and in overweight patients. Enhanced awareness initiatives, improved diagnostic capabilities, and incremental healthcare spending across global markets contribute to expanding treatment opportunities. The robust pipeline with many potential therapies under investigation positions the treatment landscape for significant market impact during the forecast period.
The market barriers include reimbursement challenges requiring proactive approaches during late-stage product development and post-launch phases. The ability to select markets with minimal reimbursement barriers becomes critical for business and pricing strategies when working with finite resources. Additional obstacles encompass poor quality of care, hepatic complications related to HCC, and morbidity associated with the disease creating challenges for market growth.
Download the Hepatocellular Carcinoma Market report to understand which other factors are driving the therapeutic market @ Hepatocellular Carcinoma Market Trends.
Conclusion
The Hepatocellular Carcinoma market stands at a pivotal transformation point, with 2025 marking unprecedented advancement through breakthrough FDA approvals, innovative device designations, and robust pipeline developments. The projected market growth to USD XX million by 2034 reflects substantial opportunities driven by rising disease incidence, enhanced therapeutic approaches, and significant unmet medical needs. The successful introduction of dual immunotherapy combinations, novel radioembolization therapies, and cutting-edge diagnostic technologies positions the market for sustained expansion across the 7MM. As pharmaceutical companies continue advancing diverse therapeutic modalities from precision immunotherapy to innovative drug conjugates, the HCC treatment landscape promises to deliver improved patient outcomes while addressing the critical challenges of this devastating malignancy.
Scope of the Hepatocellular Carcinoma Market Report
-
Comprehensive disease overview: The report covers descriptive overview of Hepatocellular Carcinoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
-
Epidemiological insights: Comprehensive insight has been provided into the Hepatocellular Carcinoma epidemiology and treatment across the 7MM markets
-
Therapeutic landscape analysis: All-inclusive account of both current and emerging therapies for Hepatocellular Carcinoma, along with assessment of new therapies impacting the current treatment landscape
-
Market forecasting: Detailed review of the Hepatocellular Carcinoma market including historical and forecasted analysis, covering drug outreach across the 7MM
-
Patient-based market trends: Detailed Patient Based Market Forecasting determining trends shaping and driving the Global Hepatocellular Carcinoma market
-
Geographic coverage: Analysis spanning United States, EU4 countries (Germany, France, Italy, Spain), United Kingdom, and Japan
-
Timeline scope: Study period covering 2020 to 2034 with forecast period from 2025 to 2034
-
Pipeline analysis: In-depth analysis of pipeline assets across Phase III and Phase II development stages, emerging trends, and comparative analysis with detailed clinical trial profiles
-
Competitive intelligence: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, and market entry strategies
-
Stakeholder insights: KOL and SME opinions through primary research to validate secondary research and identify unmet needs
-
Regulatory landscape: Coverage of FDA approvals, designations, clinical trial developments, and regulatory milestones
Table of Contents
1. Key Insights
2. Executive Summary of Hepatocellular Carcinoma
3. Competitive Intelligence Analysis for Hepatocellular Carcinoma
4. Hepatocellular Carcinoma Market Overview at a Glance
5. Hepatocellular Carcinoma: Disease Background and Overview
6. Hepatocellular Carcinoma Patient Journey
7. Hepatocellular Carcinoma Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Hepatocellular Carcinoma Unmet Needs
10. Key Endpoints of Hepatocellular Carcinoma Treatment
11. Hepatocellular Carcinoma Marketed Products
12. Hepatocellular Carcinoma Emerging Therapies
13. Hepatocellular Carcinoma: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Hepatocellular Carcinoma
17. KOL Views
18. Hepatocellular Carcinoma Market Drivers
19. Hepatocellular Carcinoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services